
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is positioned for substantial growth as it anticipates FDA approval for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology within the next year, which could significantly enhance its stock performance. The company’s product is projected to offer a more accurate and cost-effective method for diagnosing and monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing a major healthcare need for over one billion affected individuals globally. Additionally, a net present value (NPV) analysis suggests there is considerable upside potential from the current share price, reinforcing a positive outlook on the company's financial trajectory.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.6 million or EPS of $(2.10), which was worse than the estimated EPS of $(1.95), indicating ongoing financial challenges. Additionally, the firm faces multiple significant risks, including liquidity issues, potential failure in clinical trials, and hurdles related to regulatory approvals and product commercialization, which could impede its market prospects. The continuous negative financial performance alongside these substantial risks highlights a concerning outlook for the firm's ability to achieve favorable market conditions and investor confidence.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares